Drugs News and Research

RSS

Medicare steps up efforts to monitor seniors' prescriptions

Writing for Kaiser Health News in collaboration with USA Today, Susan Jaffe reports on how Medicare is expanding a program to make sure that some older adults use the right drugs and take them correctly to prevent harmful side effects or interactions.

24 Mar 2010

FDA grants Orphan Drug Designation for anti-diabetic drug

The FDA has granted Orphan Drug Designation of Diamyd Medical´s lead drug candidate Diamyd®. Orphan drugs qualify for seven years of market exclusivity from the date of US marketing approval, tax credits for clinical research and a waiver for FDA user fees.

24 Mar 2010

Renowned leaders to discuss latest findings in early-stage drug development for cancer

When people think of cancer treatment, chemotherapy infusions, injections and pills often come to mind. These treatments result from extensive research and testing in drug development. But how does the process begin?

24 Mar 2010

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

23 Mar 2010

EMA validates InterMune's pirfenidone MAA for IPF

InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.

23 Mar 2010

First Edition: March 23, 2010

Today's headlines cover a range of topics related to the newly passed health overhaul bill, from the surrounding opposition and next steps to some of its policy implications.

23 Mar 2010

New research at Tel Aviv University may lay groundwork for retinal implants in people

Television's Six Million Dollar Man foresaw a future when man and machine would become one. New research at Tel Aviv University is making this futuristic "vision" of bionics a reality.

23 Mar 2010

SAMHSA study shows how psychiatric drugs prescribed for medical conditions

A new study sponsored by the Substance Abuse and Mental Health Services Administration outlines the conditions that physicians around the country reported treating with psychiatric drugs such as antipsychotics, antidepressants, and anti-anxiety drugs.

23 Mar 2010

Researchers investigate link between consumption of high-fructose corn syrup and obesity

A Princeton University research team has demonstrated that all sweeteners are not equal when it comes to weight gain: Rats with access to high-fructose corn syrup gained significantly more weight than those with access to table sugar, even when their overall caloric intake was the same.

23 Mar 2010

Sir James Black inventor of beta-blockers passes away

Sir James Black passed away on Monday after a long illness, he was 85. Sir James Black is credited as the inventor of the beta-blocker drugs in 1962. These are drugs which play an important role in the treatment of angina and heart attacks. They are regarded as one of the major medical breakthroughs of the 20th Century in Pharmacology. Born in Uddingston, Lanarkshire, Sir James Black studied medicine at St. Andrews University.

23 Mar 2010

ChemGenex shares falter as FDA requests more data on new leukemia drug

ChemGenex Pharmaceuticals Ltd. Shares fell most in the last 16 years to AUD$0.44 following a concern raised by the US drug regulators – US FDA. The FDA requested on Monday for more uniform clinical test data before they review and consider approval of the company’s new leukemia drug.

23 Mar 2010

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 7-1 that a validated test to identify the T315I mutation should be reviewed by the FDA prior to approval of OMAPRO™ (omacetaxine mepesuccinate).

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

Some industry groups see boon in health bill

The New York Times reports that the 32 million additional Americans who would be covered by health insurance by 2019 "would mean millions more Americans buying private health insurance and better able to pay for their hospital stays, doctors' visits, prescription drugs and medical devices. And some analysts said as the vote neared that the final legislation was shaping up as much kinder to the industry than many initially feared.

23 Mar 2010

$CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval$

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Mar 2010

NPAF applauds Congressional Democrats for supporting health insurance reform

The National Patient Advocate Foundation -- a national, non-profit organization dedicated to the mission of creating avenues of improved patient access to health care through public policy reform at the state and federal levels -- today praised Congressional Democrats for their courageous support of health insurance reform that will expand health insurance coverage and restrict the ability of insurance companies to deny coverage based on pre-existing conditions.

23 Mar 2010

How the health bill would affect you

Kaiser Health News has a Q & A for consumers, detailing who would have to get health insurance, what programs are available to help them afford it and how the legislation would affect seniors and young adults (Galewitz, 3/21).

23 Mar 2010

GUMC scientists awarded five-year $7.5M grant to perfect treatment of breast cancer

Scientists at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center were awarded a five-year $7.5 million grant to tease apart - in the most comprehensive way ever devised -the role of a single protein receptor in breast cells in cancer development and treatment.

22 Mar 2010

Pharmacy provisions in health care reform bill will help pharmacists improve patient outcomes: NCPA

Pharmacy provisions included in health care reform legislation passed by the U.S. House of Representatives will improve community pharmacists' ability to improve patient outcomes and reduce costs, the National Community Pharmacists Association said today.

22 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Drugs News and Research

Medicare steps up efforts to monitor seniors' prescriptions

FDA grants Orphan Drug Designation for anti-diabetic drug

Renowned leaders to discuss latest findings in early-stage drug development for cancer

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

EMA validates InterMune's pirfenidone MAA for IPF

First Edition: March 23, 2010

New research at Tel Aviv University may lay groundwork for retinal implants in people

SAMHSA study shows how psychiatric drugs prescribed for medical conditions

Researchers investigate link between consumption of high-fructose corn syrup and obesity

Sir James Black inventor of beta-blockers passes away

ChemGenex shares falter as FDA requests more data on new leukemia drug

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Some industry groups see boon in health bill

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

NPAF applauds Congressional Democrats for supporting health insurance reform

How the health bill would affect you

GUMC scientists awarded five-year $7.5M grant to perfect treatment of breast cancer

Pharmacy provisions in health care reform bill will help pharmacists improve patient outcomes: NCPA

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News